- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05975112
The Incidence of Hyperfibrinolysis During Vaginal Delivery and Cesarean Section
Study Overview
Status
Conditions
Detailed Description
Postpartum Hemorrhage (PPH) is a potentially life-threatening complication of labour and a leading cause of maternal mortality and morbidity. It is defined as a blood loss of 500ml or more in the first 24 hours after birth and it is estimated that about 2% of all parturients are affected. Postpartum hemorrhage is responsible for 8% of maternal deaths in in industrialized nations. The prophylactic use of an uterotonic agent is suggested to reduce the risk of postpartum bleeding.
Tranexamic acid has become another candidate for the prevention of postpartum hemorrhage over the past ten years. It has an antifibrinolytic effect and inhibits hyperfibrinolysis, its clinical effects have been demonstrated in several contexts. In clinical trials outside of obstetrics, tranexamic acid has been found to reduce the need for transfusions during elective procedures and to reduce mortality in patients with extra- or intracranial trauma. In recent studies it is suggested to administer Tranexamic acid already prophylactically during cesarean delivery to reduce blood loss and avoid hyperfibrinolysis and PPH.
What is not known, is how often patients are affected by hyperfibrinolysis during cesarean section and vaginal birth without it manifesting as PPH. In trauma patients, for example, hyperfibrinolysis was found in 5% and moderate hyperfibrinolysis in 57%.
It is unusual to establish a prophylactic treatment without any data on the incidence of the condition, which is aimed to be treated. Therefore, the aim of the study is to provide a data basis for the incidence of hyperfibrinolysis after vaginal delivery and cesarean section.
Primary Aim:
The aim of this study is to quantify the incidence of hyperfibrinolysis during natural birth and C-section. For this purpose, maternal blood is drawn after the baby's cord is cut and analyzed using thrombelastography with the addition of tranexamic acid. In addition, the following parameters are examined:
- Levels of Factor 1 (Fibrinogen) and Factor 2 (Thrombin)
- Level of D-Dimer
Secondary objectives
- Mode of delivery (Vaginal delivery/ C-Section)
- Time cut to delivery as marker for increased manipulation
- Duration of birth in vaginal delivery? Onset of labor until delivery?
- Number of previous births
- Weeks of gestation
- Obstetrical risk factors (multiple gestation, polyhydramnios, prolonged labour, fever)
- Height / weight of parturient
- ASA (American Society of Anesthesiologists) status
- Anticoagulant drugs
At discharge from the delivery room, approximately 6 hours after delivery, hemoglobin levels are checked by noninvasive hemoglobin measurement (Rad-67™ Spot-check Pulse CO-Oximeter® (Masimo Corporation, Irvine, CA) and blood drawing as part of routine clinical practice. In this way, the extent of blood loss can be estimated, and as a further objective the investigators can also verify the usability of spHb (continuous total hemoglobin) measurement in the delivery room.
The usefulness of continuously measuring SpHb in a perioperative setting has previously been described. Several studies have shown that SpHb can help to estimate Hb values in various settings and to reduce unnecessary red blood cell (RBC) transfusions.
In the delivery room setting, the spHb value could serve as an additional tool to reduce unnecessary testing without the cost of overlooking anemic patients in the future.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Philipp Zoidl, MD
- Phone Number: 004331638584659
- Email: philipp.zoidl@medunigraz.at
Study Locations
-
-
Styria
-
Graz, Styria, Austria, 8010
- Recruiting
- Medical University of Graz
-
Contact:
- Philipp Zoidl, MD
- Email: philipp.zoidl@medunigraz.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women aged 18 years and older with a singleton or multiple pregnancy who volunteer for the present study and give one blood sample of 6ml
Exclusion Criteria:
- Age < 18 years
- Emergency cesarean section
- History of thrombocytopathy or coagulation disorders
- Therapy with drugs that influence thrombocyte function and coagulation (ASS less than 5 days ago, clopidogrel, prasugrel, ticagrelor or similar)
- Lack of consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
cesarean section
maternal blood is drawn immediately after the baby's cord is cut and analyzed using thrombelastography with the addition of tranexamic acid. In addition, the following parameters are examined:
SpHb is measured before discharge from the delivery room in order to estimate blood loss and to be able to make a comparison with the level of Hb measured in the laboratory as part of clinical routine. |
Coagulation tests named earlier as well as SpHb
|
vaginal delivery
maternal blood is drawn immediately after the baby's cord is cut and analyzed using thrombelastography with the addition of tranexamic acid. In addition, the following parameters are examined:
SpHb is measured before discharge from the delivery room in order to estimate blood loss and to be able to make a comparison with the level of Hb measured in the laboratory as part of clinical routine. |
Coagulation tests named earlier as well as SpHb
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Hyperfibrinolysis
Time Frame: immediate after birth
|
Ly30-Index is used as marker for Hyperfibrinolysis
|
immediate after birth
|
D-dimer
Time Frame: immediate after birth
|
D-dimer level
|
immediate after birth
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cesarean Section Complications
-
Assiut UniversityNot yet recruitingCesarean Section Complications | Cesarean Section Niche
-
Recep Tayyip Erdogan University Training and Research...CompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Ataturk UniversityUnknownCesarean Section Complications | Cesarean Section; Complications, Wound, Dehiscence | Cesarean Section, Repeated | Cesarean, Uterine Scar Thickness | Cesarean, Residual Myometrial ThicknessTurkey
-
University of CalgaryNot yet recruitingCesarean Section ComplicationsCanada
-
Peking University People's HospitalNot yet recruiting
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
Gaziosmanpasa Research and Education HospitalUnknownCesarean Section ComplicationsTurkey
-
Ain Shams UniversityUnknownCesarean Section ComplicationsEgypt
-
Mohamed Abdelrady MohamedCompletedCesarean Section ComplicationsEgypt
-
McGill University Health Centre/Research Institute...Thammasat UniversityUnknownCesarean Section ComplicationsCanada